Now the same for Break-Even, Revenue and Profitability
Have used the aid of Ai to extract some transcript from the Webinar, and then more Ai to create a summary of that with particular focus on Break-Even, Revenue and Profitability. What is printed below is not word for word what the CEO said, it is rather an Ai summary which is quite accurate I believe - but DYOR, do not rely on this Ai generated webinar summary to make investment decisions, best you listen to the Youtube recording instead.
here is the Ai summarised Break-Even, Revenue and Profitability part of it :Break-Even, Revenue, and Profitability
Ryan Soutar: Nigel, could you provide us with details regarding the company's path to break-even, revenue expectations, and overall profitability?
Nigel Lange: Certainly, these are key aspects of our financial strategy and growth trajectory. Here's a comprehensive look at our current expectations and plans:
Capital Raise and Cash RunwayCapital Raise Impact:
- The recent capital raise has significantly strengthened our financial position. The proceeds from the raise are expected to extend our cash runway through to the end of next calendar year.
- This extended cash runway provides us with the necessary resources to continue our commercialization efforts and achieve critical regulatory milestones.
Break-Even PointTimeline to Break-Even:
- We anticipate reaching the break-even point by the last quarter of 2025 or the first quarter of 2026. This timeline is based on our current revenue projections and market expansion plans.
- An uptick in sales is crucial to reaching this milestone. We are seeing positive signs from our various initiatives, and we expect these to bear fruit in the near term.
Revenue GrowthSales and Revenue Projections:
- There has been an observed uptick in sales, which is promising for our revenue growth. While I cannot disclose specific numbers, I am pleased with the current quarter's performance.
- Market expansion in regions like Italy, Spain, Greece, and Israel is expected to drive revenue growth. Italy, in particular, is poised to follow Spain as a leader in adopting our technology, thanks to recent changes in our market strategy that open up more reimbursement opportunities.
New Markets Contribution:
- Entry into new markets such as Turkey and Saudi Arabia, as well as potential approval in South Korea, will further enhance our revenue streams. These markets offer substantial opportunities due to their large patient populations and favorable healthcare coverage.
Financial Strategy and PlanningRevenue from G-BA Approval:
- While our break-even projections do not currently factor in potential revenue from the German G-BA approval, obtaining this approval would significantly accelerate our path to profitability. The G-BA approval would allow us to negotiate commercial treatments with numerous hospitals, providing a substantial revenue boost.
Reimbursement and Sales Expansion:
- Geographic expansion is a key part of our strategy to increase revenue. By entering new markets and securing reimbursement in regions like Europe and the US, we can tap into larger patient populations and enhance our sales volume.
- The recent opening of the Turkish market and the first patient treatment there marks the beginning of a potentially robust market, expected to develop significantly over the next six months.
Summary on Financial OutlookBreak-Even and Profitability:
- We are confident in our plan to reach the break-even point by the end of 2025 or early 2026, driven by increased sales, market expansion, and strategic use of the capital raised.
- Our ongoing efforts to secure regulatory approvals, expand into new markets, and enhance our reimbursement opportunities are all geared towards achieving sustainable revenue growth and profitability.
Nigel Lange: To summarize, our financial strategy is focused on extending our cash runway, driving revenue growth through market expansion, and strategically planning for break-even and profitability. The positive sales trends and new market opportunities are key components that will help us achieve these financial goals.
- Forums
- ASX - By Stock
- OSL
- Ann: 200th patient treated with the OncoSil device
Ann: 200th patient treated with the OncoSil device, page-45
-
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
|
|||||
Last
1.2¢ |
Change
0.001(9.09%) |
Mkt cap ! $45.40M |
Open | High | Low | Value | Volume |
1.1¢ | 1.2¢ | 1.1¢ | $18.92K | 1.705M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 13619110 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 5063491 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 13469110 | 0.010 |
23 | 14339583 | 0.009 |
10 | 6887500 | 0.008 |
13 | 6339285 | 0.007 |
8 | 8595000 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 4158618 | 8 |
0.013 | 11108832 | 8 |
0.014 | 6187166 | 8 |
0.015 | 8500000 | 3 |
0.016 | 4766668 | 3 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online